Rice Alliance names most promising life science companies at annual forum

Best of the best

Here's what life science startups were named most promising at the recent Rice Alliance Texas Life Science Forum.. Getty Images

Houston hosted an annual meeting of the minds that included thoughtful discussions, presentations, panels, and startup pitches within the life science industry.

The Texas Life Science Forum, organized and hosted by the Rice Alliance and BioHouston, took place on November 6 at Rice University's Bioscience Research Collaborative. Throughout the day, over 50 life science startups pitched to the audience. At the end of the forum, 10 startups — most of which are based in Houston — were recognized as being the most promising.

Here's what life science startups you should be keeping an eye out for.

Abilitech Medical

Photo via abilitechmedical.com

A St. Paul, Minnisota-based medical device company, Abilitech Medical develops assistive technology to Multiple sclerosis, Muscular Dystrophy, Parkinson's and stroke patients. The first product, Alibitech Assist, will be cleared by the FDA in 2020, with other devices to follow in 2022 and 2023.

AgilVax

Photo via agilvax.com

Based in Albuquerque, New Mexico, AgilVax is a biopharmaceutical company that works with chemotherapy, checkpoint and KRAS inhibitors to fight various cancers. The company's AX09 is an immunotherapeutic that is headed for human clinical trials in 2020. Another product, M5, is a monoclonal antibody currently in preclinical trials.

Altoida

Photo via altoida.com

Altoida, based in Houston, has created a medical device that uses artificial intelligence and augmented reality to collect functional and cognitive data in patients to determine their risk Mild Cognitive Impairment from Alzheimer's Disease. The Altoida Neuro Motor Index has been cleared by the FDA and CE and detects cognitive decline with a 94 percent diagnostic accuracy six to 10 years ahead of the onset of symptoms.

ColubrisMX

Photo via Pexels

Houston-based ColubrisMX makes surgical robots specializing in minimally invasive and endoluminal surgeries. The company's team of engineers and surgeons works adjacent to the Texas Medical Center.

Cord Blood Plus

Photo via Getty Images

Cord Blood Plus, based in Galveston, is working to commercialize its human umbilical cord blood stem cell technology. The company's primary mission is to use its research and treatment on breast cancer patients undergoing chemotherapy in order to prevent infections, speed up recovery, and shorten hospital stays.

CorInnova

Photo via CorInnova.com

Another Houston company, CorInnova is a medical device company that has developed a cardiac assist device to treat heart failure without many of the consequences from standard treatment. The device is able to self expand and gently compress the heart in sync with the heartbeat.

Mesogen

Photo via Mesogen.com

Mesogen, which is based in The Woodlands, is in the business of using a patient's own cells to grow a human kidney for transplant. The tissue engineering technology allows for the creation of a kidney in less than a year with less risk of transplant rejection and a better quality of life over dialysis treatment.

Saranas

Courtesy of Saranas

Houston-based Saranas has created its Early Bird device to more quickly and more accurately detect bleeding in the human body. The company, which underwent successful clinical trials last year, recently received FDA clearance and launched the device in the United States.

Stream Biomedical

Photo via streambiomedical.com

Stream Biomedical Inc. is tapping into a therapeutic protein that has proven to be neuroprotective and neuroreparative. The Houston company is aiming to apply the treatment in acute stroke cases and later for traumatic brain injury, Alzheimer's, and dementia cases.

VenoStent

Photo via venostent.com

Houston-based VenoStent has created a device that allows a successful stent implementation on the first try. VenoStent's SelfWrap is made from a shape-memory polymer that uses body heat to mold the stent into the vein-artery junction.

From Your Site Articles

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Texas falls to bottom of national list for AI-related job openings

jobs report

For all the hoopla over AI in the American workforce, Texas’ share of AI-related job openings falls short of every state except Pennsylvania and Florida.

A study by Unit4, a provider of cloud-based enterprise resource planning (ERP) software for businesses, puts Texas at No. 49 among the states with the highest share of AI-focused jobs. Just 9.39 percent of Texas job postings examined by Unit4 mentioned AI.

Behind Texas are No. 49 Pennsylvania (9.24 percent of jobs related to AI) and No. 50 Florida (9.04 percent). One spot ahead of Texas, at No. 47, is California (9.56 percent).

Unit4 notes that Texas’ and Florida’s low rankings show “AI hiring concentration isn’t necessarily tied to population size or GDP.”

“For years, California, Texas, and New York dominated tech hiring, but that’s changing fast. High living costs, remote work culture, and the democratization of AI tools mean smaller states can now compete,” Unit4 spokesperson Mark Baars said in a release.

The No. 1 state is Wyoming, where 20.38 percent of job openings were related to AI. The Cowboy State was followed by Vermont at No. 2 (20.34 percent) and Rhode Island at No. 3 (19.74 percent).

“A company in Wyoming can hire an AI engineer from anywhere, and startups in Vermont can build powerful AI systems without being based in Silicon Valley,” Baars added.

The study analyzed LinkedIn job postings across all 50 states to determine which ones were leading in AI employment. Unit4 came up with percentages by dividing the total number of job postings in a state by the total number of AI-related job postings.

Experts suggest that while states like Texas, California and Florida “have a vast number of total job postings, the sheer volume of non-AI jobs dilutes their AI concentration ratio,” according to Unit4. “Moreover, many major tech firms headquartered in California are outsourcing AI roles to smaller, more affordable markets, creating a redistribution of AI employment opportunities.”

Houston energy trailblazer Fervo closes $462 million Series E

Fresh Funds

Houston-based geothermal energy company Fervo Energy has closed an oversubscribed $462 million series E funding round, led by new investor B Capital.

“Fervo is setting the pace for the next era of clean, affordable, and reliable power in the U.S.,” Jeff Johnson, general partner at B Capital, said in a news release.

“With surging demand from AI and electrification, the grid urgently needs scalable, always-on solutions, and we believe enhanced geothermal energy is uniquely positioned to deliver. We’re proud to support a team with the technical leadership, commercial traction, and leading execution capabilities to bring the world’s largest next-generation geothermal project online and make 24/7 carbon-free power a reality.”

The financing reflects “strong market confidence in Fervo’s opportunity to make geothermal energy a cornerstone of the 24/7 carbon-free power future,” according to the company. The round also included participation from Google, a longtime Fervo Partner, and other new and returning investors like Devon Energy, Mitsui & Co., Ltd., Mitsubishi Heavy Industries and Centaurus Capital. Centaurus Capital also recently committed $75 million in preferred equity to support the construction of Cape Station Phase I, Fervo noted in the release.

The latest funding will support the continued buildout of Fervo’s Utah-based Cape Station development, which is slated to start delivering 100 MW of clean power to the grid beginning in 2026. Cape Station is expected to be the world's largest next-generation geothermal development, according to Fervo. The development of several other projects will also be included in the new round of funding.

“This funding sharpens our path from breakthrough technology to large-scale deployment at Cape Station and beyond,” Tim Latimer, CEO and co-founder of Fervo, added in the news release. “We’re building the clean, firm power fleet the next decade requires, and we’re doing it now.”

Fervo recently won Scaleup of the Year at the 2025 Houston Innovation Awards, and previously raised $205.6 million in capital to help finance the Cape Station earlier this year. The company fully contracted the project's capacity with the addition of a major power purchase agreement from Shell this spring. Fervo’s valuation has been estimated at $1.4 billion and includes investments and support from Bill Gates.

“This new investment makes one thing clear: the time for geothermal is now,” Latimer added in a LinkedIn post. “The world desperately needs new power sources, and with geothermal, that power is clean and reliable. We are ready to meet the moment, and thrilled to have so many great partners on board.”

---

This article originally appeared on EnergyCapitalHTX.com.

Baylor center receives $10M NIH grant to continue rare disease research

NIH funding

Baylor College of Medicine’s Center for Precision Medicine Models received a $10 million, five-year grant from the National Institutes of Health last month that will allow it to continue its work studying rare genetic diseases.

The Center for Precision Medicine Models creates customized cell, fly and mouse models that mimic specific genetic variations found in patients, helping scientists to better understand how genetic changes cause disease and explore potential treatments.

The center was originally funded by an NIH grant, and its models have contributed to the discovery of several new rare disease genes and new symptoms caused by known disease genes. It hosts an online portal that allows physicians, families and advocacy groups to nominate genetic variants or rare diseases that need further investigation or new treatments.

Since its founding in 2020, it has received 156 disease/variant nominations, accepted 63 for modeling and produced more than 200 precision models, according to Baylor.

The center plans to use the latest round of funding to bring together more experts in rare disease research, animal modeling and bioinformatics, and to expand its focus and model more complex diseases.

Dr. Jason Heaney, associate professor in the Department of Molecular and Human Genetics at BCM, serves as the lead principal investigator of the center.

“The Department of Molecular and Human Genetics is uniquely equipped to bring together the diverse expertise needed to connect clinical human genetics, animal research and advanced bioinformatics tools,” Heaney added in the release. “This integration allows us to drive personalized medicine forward using precision animal models and to turn those discoveries into better care for patients.”

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME